Healthcare | September 22, 2025
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
The inspection concluded with zero form 483 observations
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
